Purpose: High-dose cisplatin is standard in head and neck cancers. Recently, weekly low-dose platinum alone or with cetuximab has been used. All patients received 70 Gy standard fraction intensity-modulated radiation therapy. We are comparing the former used at the VAMC with the latter regimens used in the department of Oncology at the University of Mississippi. We will present the toxicity, response, patterns of failure, and survival by the use of the different types of chemotherapy.
Conference Coverage
Comparison of Low-Dose Platinum vs High-Dose Platinum vs Cetuximab and Intensity-Modulated Radiation Therapy in Advanced Head and Neck Cancers
Giri S, Kankamedhala M, Suggs JM.
Publish date: September 4, 2014
Abstract 7: 2014 AVAHO Meeting
Recommended Reading
Clinical Topics
-
When cisplatin won’t do, try carboplatin in head and neck cancer -
Is early-onset cancer an emerging global epidemic? Publish date: October 5, 2022 -
Despite benefits, extended-interval pembro uptake remains low Publish date: September 28, 2022 -
Time to cancer diagnoses in U.S. averages 5 months Publish date: September 15, 2022 -
Trends in Palliative Care Utilization and Facility Type for Stage IV Esophageal Cancer: A National Cancer Database Analysis
Digital Edition
-
Publish date: September 22, 2021
-
Publish date: September 3, 2021
-
Publish date: May 20, 2021
-
-
Multimedia
-
Publish date: September 14, 2014
Conference Coverage
-
A farewell to arms? Drug approvals based on single-arm trials can be flawed Publish date: September 19, 2022 -
Time to cancer diagnoses in U.S. averages 5 months Publish date: September 15, 2022 -
Pembro/chemo combo fails to improve event-free survival in head and neck cancer Publish date: September 14, 2022 -
First drug for desmoid tumors: ‘Impressive’ data for nirogacestat Publish date: September 13, 2022 -
Collagen ‘tile’ delivers postsurgical radiation in glioblastoma Publish date: June 10, 2022 -
Can liquid biopsy predict oropharyngeal cancer recurrence? Publish date: March 3, 2022 -
Confirmed: Pembro plus chemo as first-line standard of care for esophageal cancer Publish date: February 1, 2022 -
Many patients, doctors unaware of advancements in cancer care Publish date: October 4, 2021 -
Most community-based oncologists skip biomarker testing Publish date: September 21, 2021 -
Publish date: May 3, 2021
ATA Guidelines: Lymph node dissection & DTC

Question 1 of 5